XXXX associated with sexual activity: prognosis and treatment options.

@entity1 @entity3352 @entity10 @entity102
The aim of this study was to provide data on the prognosis and treatment options of @entity10 associated with sexual activity (HSA). Sixty @entity1 diagnosed with HSA between 1996 and 2004 were followed up between 2003 and 2006 at least 12 months after the first interview. The further course of the disease and their contentedness with therapy were requested. On average, the second interview was performed 35.9 months after the first examination. Of the 45 @entity1 who had suffered from single attacks or bouts prior to baseline examination, 37 had no further attacks. Seven @entity1 suffered from at least one further bout with an average duration of 2.1 months. One @entity1 developed a chronic course of the disease after an episodic start. Of the 15 @entity1 with @entity102 at the first examination, seven were in remission and five had ongoing attacks at follow-up. Ten @entity1 received @entity3352 for preemptive therapy, with good results in nine @entity1 . Eighteen @entity1 received beta-blockers for prophylaxis, with good results in 15 @entity1 . Episodic HSA occurs in approximately three-quarters and chronic HSA in approximately one-quarter of @entity1 . Even in chronic HAS, the prognosis is favourable, with remission rates of 69% during an observation period of 3 years. For @entity1 with longer-lasting bouts or with chronic HSA, prophylactic treatment with beta-blockers or preemptive therapy with @entity3352 are often successful.
